Physician profile
Robert Branch
NPI 1154381101
$5,945.20
in general payments reported to CMS, 2019-2025
21 companies · $973 in 2025
The $973 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $917 · 2020: $162 · 2021: $432 · 2022: $1,060 · 2023: $1,320 · 2024: $1,080 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,373.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,133.36 | 2019-2025 | Total30, Precision7, Clareon |
| Johnson & Johnson Vision Care, INC. | $872.66 | 2019-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $597.42 | 2021-2024 | Cequa, Xelpros |
| Bausch & Lomb Americas INC. | $487.67 | 2022-2025 | Infuse, Xiidra, Vyzulta |
| Allergan, INC. | $465.20 | 2020-2022 | |
| Abbvie INC. | $426.60 | 2023-2025 | Vuity, Lumigan, Alphagan P |
| Coopervision INC. | $341.73 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Novartis Pharmaceuticals Corporation | $333.79 | 2019-2023 | |
| Oyster Point Pharma, INC. | $239.87 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Shire North American Group INC | $158.74 | 2019 | |
| Glaukos Corporation | $135.23 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $125.00 | 2019 | |
| Sight Sciences, INC. | $119.80 | 2022-2023 | Omni Surgical System |
| Mallinckrodt Hospital Products INC. | $111.74 | 2025 | Acthar |
| Optos, INC. | $101.97 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lkc Technologies, INC. | $97.65 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $59.21 | 2025 | Xdemvy |
| Dompe US, INC. | $57.28 | 2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $31.39 | 2021 | |
| Abb Con-Cise Optical Group LLC | $28.55 | 2019-2020 | |
| Harrow Eye, LLC | $20.34 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Branch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.